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Background and Purpose—Recent positive randomized trials of endovascular therapy for ischemic stroke used predominantly 
stent retrievers. We pooled data to investigate the efficacy and safety of stent thrombectomy using the Solitaire device in 
anterior circulation ischemic stroke.
Methods—Patient-level data were pooled from trials in which the Solitaire was the only or the predominant device used 
in a prespecified meta-analysis (SEER Collaboration): Solitaire FR With the Intention for Thrombectomy as Primary 
Endovascular Treatment (SWIFT PRIME), Endovascular Treatment for Small Core and Anterior Circulation Proximal 
Occlusion With Emphasis on Minimizing CT to Recanalization Times (ESCAPE), Extending the Time for Thrombolysis 
in Emergency Neurological Deficits—Intra-Arterial (EXTEND-IA), and Randomized Trial of Revascularization With 
Solitaire FR Device Versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large 
Vessel Occlusion Presenting Within Eight Hours of Symptom Onset (REVASCAT). The primary outcome was ordinal 
analysis of modified Rankin Score at 90 days. The primary analysis included all patients in the 4 trials with 2 sensitivity 
analyses: (1) excluding patients in whom Solitaire was not the first device used and (2) including the 3 Solitaire-only trials 
(excluding ESCAPE). Secondary outcomes included functional independence (modified Rankin Score 0–2), symptomatic 
intracerebral hemorrhage, and mortality.
Results—The primary analysis included 787 patients: 401 randomized to endovascular thrombectomy and 386 to standard 
care, and 82.6% received intravenous thrombolysis. The common odds ratio for modified Rankin Score improvement 
was 2.7 (2.0–3.5) with no heterogeneity in effect by age, sex, baseline stroke severity, extent of computed tomography 
changes, site of occlusion, or pretreatment with alteplase. The number needed to treat to reduce disability was 2.5 and 
for an extra patient to achieve independent outcome was 4.25 (3.29–5.99). Successful revascularization occurred in 77% 
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The management of ischemic stroke because of large ves-sel occlusion has been transformed by the publication of 
5 positive randomized trials which predominantly used stent 
retrievers.1–5 These trials have led to highest-level guide-
line recommendations in the United States,6 Europe,7 and 
Canada8 supporting mechanical stent thrombectomy within 6 
hours of ischemic stroke onset for patients with large vessel 
stroke because of internal carotid and middle cerebral artery 
occlusions.
Although each trial was positive in its own right and no 
major subgroup heterogeneity was observed in the individual 
trials, the power to detect subgroup effects was low and preci-
sion of effect size measures was limited. Further, there was 
variation in the device and procedural approach used in the tri-
als. Multiple study-level meta-analyses of summary trial data 
have been published.9–11 However, individual pooled patient 
data meta-analysis, similar to that performed for intravenous 
thrombolysis, adds power, improves precision, and allows 
accurate interrogation of subgroups.12
The trialists have agreed to pool individual patient data 
to address these outstanding questions. In a separate report, 
data from all 5 trials is being analyzed to clarify aspects of 
treatment across diverse device therapies. The purpose of 
the current report is to examine treatment effects in patients 
treated specifically with the most common device used in the 
pivotal trials, the Solitaire stent retriever (Medtronic, Dublin, 
Ireland).
Methods
For this report specifically analyzing the Solitaire device, studies 
were eligible for the primary analysis if they met the following se-
lection criteria: (1) randomized trial of endovascular thrombectomy 
added to best medical therapy versus best medical therapy alone, with 
the Solitaire device used first in all or a majority of the interventions 
and (2) imaging confirmation of large vessel occlusion before study 
entry. Four trials met these criteria and were included in the prima-
ry analysis (SEER Collaboration): Solitaire FR With the Intention 
for Thrombectomy as Primary Endovascular Treatment (SWIFT 
PRIME), Endovascular Treatment for Small Core and Anterior 
Circulation Proximal Occlusion With Emphasis on Minimizing 
CT to Recanalization Times (ESCAPE), Extending the Time for 
Thrombolysis in Emergency Neurological Deficits—Intra-Arterial 
(EXTEND-IA), and Randomized Trial of Revascularization With 
Solitaire FR Device Versus Best Medical Therapy in the Treatment 
of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion 
Presenting Within Eight Hours of Symptom Onset (REVASCAT). The 
Multicenter Randomized Clinical Trial of Endovascular Treatment 
for Acute Ischemic Stroke in the Netherlands (MR CLEAN) trial was 
not included because the Solitaire device was used in only a minority 
of the interventions (but is included in a separately reported, larger 
analysis not focused on the Solitaire device).
Data from each trial were collated by an independent statistical 
center which performed analyses according to a prespecified statis-
tical analysis plan (available in the online-only Data Supplement). 
Commonalities and differences in trial characteristics are summa-
rized in Table I in the online-only Data Supplement. The primary 
analysis included all patients enrolled in all 4 trials. Two sensitivity 
analyses were performed: (1) including in the endovascular arm only 
those patients in whom the first device actually used was Solitaire or 
would have been Solitaire had a target clot been still present and ac-
cessible (Solitaire intention to treat analysis) and (2) including only 
patients from the 3 trials that universally used Solitaire in the endo-
vascular arm (SWIFT PRIME, EXTEND-IA, and REVASCAT). The 
primary outcome was degree of disability as assessed on the modified 
Rankin scale (mRS) at 90 days.
Prespecified subgroup analyses were age (<70 years of age versus 
≥70 years and <80 years of age versus ≥80 years), sex (male/female), 
stroke severity (National Institutes of Health Stroke Scale [NIHSS] 
≤15, 16–20, and ≥21), site of intracranial vascular occlusion (in-
ternal carotid artery, M1 and M2 middle cerebral artery), presence 
of tandem cervical carotid occlusion (yes/no), extent of initial 
early ischemic changes (Alberta Stroke Program Early CT Score 
[ASPECTS] 0–5, 6–8, and 9–10), administration of alteplase (yes/
no), and time from onset to randomization (<5 h and ≥5 h). Onset to 
randomization dichotomization at 5 h was chosen to approximate the 
subgroup who could have endovascular treatment commenced within 
6 h of onset. In addition, patients treated with alteplase within 3 hours 
of stroke onset (FDA label for alteplase) were examined.
Prespecified secondary efficacy outcomes were independent 
functional outcome (mRS 0–2) at 90 days; major early neurologi-
cal recovery at 24 h, defined as a reduction in NIHSS from baseline 
of at least 8 points or reaching 0 to 1; and the rate of successful re-
vascularization at end of endovascular procedure defined as modified 
Treatment in Cerebral Ischemia (mTICI) 2b/3 representing restora-
tion of blood flow to >50% of the affected territory. For this analysis, 
final revascularization in ESCAPE patients was reclassified so that 
all trials used the mTICI scale which demarcates 2b as 50% to 99% 
restoration of blood flow to the affected territory.13
Safety outcomes examined were symptomatic intracerebral hem-
orrhage (as defined by the source trial, see Table I in the online-only 
Data Supplement) and mortality. The rate of radiologically defined 
parenchymal hematoma was also reported.
The technical efficacy and safety of the Solitaire device was also 
assessed in all patients in the 4 trials in which Solitaire was actually 
used as the first device deployed. This as-treated population did not 
include patients randomized to the endovascular arm who did not re-
ceive a device either because they had already reperfused by the time 
of catheter angiography or navigation to the target occlusion could 
not be accomplished.
Statistical analysis was performed by the independent statisti-
cian who merged the individual trial databases and used SAS v.9.2 
(SAS Institute, Cary, NC). The primary outcome was analyzed using 
mixed methods ordinal logistic regression with mRS categories 5 and 
6 merged and study and trial-by-treatment interaction as random ef-
fects variables. Because the trials were conducted independently, 
in different geographic locations and health systems, the statistical 
analysis plan specified random rather than fixed effects to avoid the 
assumption of a common effect size among these trials. Unadjusted 
and adjusted models were analyzed. The adjusted analysis included 
treated with Solitaire device. The rate of symptomatic intracerebral hemorrhage and overall mortality did not differ 
between treatment groups.
Conclusions—Solitaire thrombectomy for large vessel ischemic stroke was safe and highly effective with substantially 
reduced disability. Benefits were consistent in all prespecified subgroups.   (Stroke. 2016;47:798-806. DOI: 10.1161/
STROKEAHA.115.012360.)
Key Words: endovascular treatment ◼ intra-arterial therapy ◼ ischemic stroke ◼ mechanical thrombectomy  
◼ meta-analysis ◼ randomized controlled trial ◼ stent retriever device ◼ thrombolysis
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7 prespecified covariates: age, sex, baseline stroke severity, site of oc-
clusion, intravenous alteplase treatment, ASPECTS score, and time 
from onset to randomization. Number needed to treat (NNT) values 
reflecting concurrent transitions across multiple mRS levels were de-
rived by calculating the geometric mean of the NNT values yielded 
by the algorithmic joint outcome table method and the permutation 
test method (combining mRS categories 5 and 6).14,15 The secondary 
dichotomous outcomes were analyzed using binary logistic regression 
with the same covariates and study and trial-by-treatment interaction 
as random effects variables. NNT for dichotomous outcomes was 
calculated as 100/absolute risk reduction. Assessment of time of re-
perfusion as a predictor of outcome was conducted separately in the 
intervention group. The adjusted probability of independent outcome 
in the intervention group that achieved mTICI 2b/3 reperfusion was 
solved using a hierarchical generalized linear mixed model with study 
as a random variable and onset-to-reperfusion time. Probabilities were 
graphed as a function of time with the probability of independent out-
come regressed against time using simple linear regression to produce 
an estimate of effect size for each unit of time delay to treatment.
Results
Characteristics of the Patients
In total, the primary analytic population included 787 anterior 
circulation ischemic stroke patients, 401 randomized to stent 
thrombectomy and 386 to standard care. Of these, 650/787 
(82.6%) received intravenous thrombolysis (Table 1). In the 
first sensitivity analysis, the Solitaire-first intention to treat, 
the population included 713 patients, 327 randomized to 
thrombectomy and 386 to standard care. In the second sen-
sitivity analysis, of the 3 Solitaire-only trials, there were 472 
Table 1. Patient and Procedural Characteristics for the Four 
Trials: SWIFT PRIME, ESCAPE, EXTEND-IA, and REVASCAT
Characteristic Control Intervention
Number 386 401
Age, y, mean (SD) 67.8 (12.3) 67.3 (12.7)
Male sex, n (%) 193 (50.0) 195 (48.6)
Race, n (%)  
  White 347 (89.9) 357 (89.0)
  Black 14 (3.6) 18 (4.5) 
  Asian 13 (3.4) 11 (2.7) 
  Other 12 (3.1) 15 (3.7)
NIHSS score, median (interquartile 
range)
17 (12–19) 17 (13–20)
Previously diagnosed atrial  
fibrillation, n (%)
146 (37.8) 143 (35.7)
Hypertension, n (%) 259 (67.1) 254 (63.3)
Diabetes mellitus, n (%) 54 (14.0) 48 (12.0)
Current or past tobacco use, n (%) 132 (34.2) 129 (32.2)
Serum glucose, mg/dL, mean (SD) 131.8 (48.3) 128.7 (39.8)
Time (min) from stroke onset to 
hospital arrival, median  
(interquartile range)
108 (58–206) 105 (55–199)
Treatment with intravenous  
alteplase, n (%)
327 (84.7) 323 (80.5)
Time (min) from stroke onset to 
initiation of alteplase, median 
(interquartile range)
120 (89–164) 114 (86–150)
Time from hospital arrival to initiation 
of intravenous alteplase (door-to- 
needle), min, median (interquartile 
range)
38 (26–57) 36 (24–54)
Time from initiation of intravenous 
alteplase to randomization, min, 
median (interquartile range)
51 (18–123) 48 (21–109)
Site of vessel occlusion, n (%)
Internal carotid artery (ICA) 66 (17.1) 73 (18.2)
First segment of middle cerebral 
artery (M1)
287 (74.4) 285 (71.1)
Second segment of middle cerebral 
artery (M2)
23 (6.0) 33 (8.2)
Not recorded 10 (2.6) 10 (2.5)
Noncontrast CT ASPECTS median 
(interquartile range)
9 (7–10) 9 (7–10)
Time (min) from stroke onset to 
arterial access, median (interquartile 
range)
N/A 225 (157–302)
Time (min) from hospital arrival to 
arterial access, median (interquartile 
range)
N/A 93 (69–127)
Time (min) from initial imaging to 
arterial access, median (interquartile 
range)
N/A 63 (46–85)
Time (min) from alteplase 
commencement to arterial access, 
median (interquartile range)
N/A 68 (43–103)
(Continued )
Time (min) from arterial access to 
mTICI 2b/3 or completion, median 
(interquartile range)
N/A 38 (24–60)
Time (min) from stroke onset to 
mTICI 2b/3 or completion, median 
(interquartile range)
N/A 274 (196–365)
Final mTICI, n (%)
  3 N/A 132 (32.9) 
  2b 153 (38.2)
  2a 62 (15.5)
  1 6 (1.5)
  0 19 (4.7)
  Angiogram not performed 29 (7.2)
mTICI as assessed by individual trial core laboratory. Scale ranges from 
no flow (0) to normal flow (3). mTICI 2b is restoration of flow to >50% of 
the affected arterial territory.13 NIHSS score (standardized neurological 
examination) ranges from normal (0) to death (42). No statistically significant 
differences between groups. ASPECTS indicates Alberta Stroke Program 
Early CT Score; ESCAPE, Endovascular Treatment for Small Core and 
Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to 
Recanalization Times; EXTEND-IA, Extending the Time for Thrombolysis in 
Emergency Neurological Deficits—Intra-Arterial; mTICI, modified Treatment 
in Cerebral Ischemia; NIHSS, National Institutes of Health Stroke Scale; 
REVASCAT, Randomized Trial of Revascularization With Solitaire FR Device 
Versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior 
Circulation Large Vessel Occlusion Presenting Within Eight Hours of Symptom 
Onset; and SWIFT PRIME, Solitaire FR With the Intention for Thrombectomy as 
Primary Endovascular Treatment.
Table 1. Continued
Characteristic Control Intervention
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patients, including 236 randomized to endovascular interven-
tion and 236 to standard care (Tables II and III in the online-
only Data Supplement).
Primary Outcome
In the primary analysis, the common odds ratio (OR) for 
improvement in ordinal analysis of mRS was 2.4 (1.8–3.0; 
P=0.0000000001) unadjusted and common OR 2.7 (2.0–
3.5; P<0.0000000001) adjusted—an NNT of 2.5 patients to 
improve at least one level on the mRS (Table 2 and Figures 
1 and 2A). Effects were similar in the 2 sensitivity analyses 
(Figure 1; Figures I and II and Tables IV and V in the online-
only Data Supplement) and in patients who received alteplase 
within 3 hours of stroke onset (Table VI in the online-only 
Data Supplement). There was no heterogeneity in effect in 
subgroup analysis by age, sex, baseline stroke severity, pre-
treatment thrombolysis, site of intracranial vascular occlusion, 
time from onset to randomization, or extent of initial noncon-
trast computed tomography abnormalities, with the exception 
of the Solitaire as first device population where there was het-
erogeneity in treatment effect by baseline ASPECTS score, 
P=0.02 (Figures 2B, 2C and 3). Findings were similar in the 
2 sensitivity analysis populations (Figures III and IV in the 
online-only Data Supplement).
Secondary Outcomes and Safety
Benefit was seen in all secondary efficacy outcomes. The NNT 
to achieve an extra patient with independent outcome (mRS 
0–2) was 4.25 (95% confidence interval 3.29–5.99; Table 2). 
Major early neurological recovery was substantially increased 
in the Solitaire-treated patients. Findings were similar in the 2 
sensitivity analysis populations (Tables IV and V in the online-
only Data Supplement). In a simpler fixed effects model, there 
was no evidence of a study-by-treatment interaction, indicat-
ing homogeneity of effect across all 4 trials (P=0.513).
In the safety analyses, there were no significant differ-
ences in symptomatic hemorrhage or mortality overall (Table 
2). There was, however, a significant reduction in mortality in 
the subgroup aged ≥80 in the complete SEER data set (20% 
versus 40%, adjusted OR 3.7 [1.3–10.6; P=0.01]; Figure 
2C) with similar trend in the Solitaire sensitivity population 
(Figure IIIC in the online-only Data Supplement). Results 
were similar in those treated with alteplase within 3 hours ver-
sus 3 to 4.5 hours after stroke onset (Tables VI–VIII in the 
online-only Data Supplement).
In the technical efficacy analysis, among patients from all 
4 trials harboring persisting occlusions at catheter angiogra-
phy and actually treated with Solitaire as first device used, 
the rate of successful revascularization (mTICI 2b/3) was 
236/306 (77%). Rates of mRS 0 to 2 increased with each suc-
cessive category of mTICI (P=0.01 for trend; Table IX in the 
online-only Data Supplement). There was a small but signifi-
cant reduction in the proportion of Solitaire-treated patients 
achieving independent outcome as time from onset to reperfu-
sion increased (Figure 4).
Discussion
This individual patient data meta-analysis has demonstrated 
robust benefit of Solitaire stent thrombectomy. The degree of 
benefit conferred is substantial, with 40 of every 100 patients 
treated having reduced disability as a result of thrombectomy, 
including 23 patients achieving an independent outcome. No 
major safety concerns were noted, with no increase in symp-
tomatic hemorrhage or mortality. Benefit was homogenous 
across a broad range of patients, including younger and older, 
male and female, internal carotid and middle cerebral artery 
Table 2. Patient Outcomes in Primary Analysis: SWIFT PRIME, ESCAPE, EXTEND-IA, REVASCAT
Outcome
Control 
(n=386)
Intervention 
(n=401)
Adjusted* Unadjusted
Effect Size OR (95% CI) P Value Effect Size OR (95% CI) P Value
Primary outcome: functional outcome at 90 days (modified 
Rankin Scale, mRS) ordinal analysis, median (IQR)†
4 (2–5) 2 (1–4) 2.7 (2.0–3.5) <0.0001 2.4 (1.8–3.0) <0.0001
Secondary outcomes: independent functional outcome (mRS 0-2) 119 (31.5%) 216 (54.0%) 3.1 (2.2–4.4) <0.0001 2.6 (1.9–3.5) <0.0001
Excellent functional outcome (mRS 0–1) 67 (17.7%) 143 (35.8%) 3.0 (2.1–4.3) <0.0001 2.6 (1.9–3.7) <0.0001
Early neurological improvement (NIHSS reduction ≥8 points or 
reaching 0–1 at 24 h)‡
100 (25.9%) 240 (59.9%) 4.8 (3.5–6.7) <0.0001 4.3 (3.1–5.8) <0.0001
Safety
  Death 63 (16.3%) 48 (12.0%) 0.64 (0.35–1.2) 0.16 0.69 (0.43–1.1) 0.12
  Symptomatic intracerebral hemorrhage§ 11 (2.8%) 10 (2.5%) 0.78 (0.31–1.9) 0.58 0.87 (0.36–2.1) 0.76
  Parenchymal hematoma (PH) 31 (8.0%) 32 (8.0%) 0.96 (0.56–1.6) 0.89 1.0 (0.57–1.8) 0.96
CI indicates confidence interval; CT, computed tomography; ESCAPE, Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With 
Emphasis on Minimizing CT to Recanalization Times; EXTEND-IA, Extending the Time for Thrombolysis in Emergency Neurological Deficits—Intra-Arterial; IQR, 
interquartile range; mRS, modified Rankin Scale; REVASCAT, Randomized Trial of Revascularization With Solitaire FR Device Versus Best Medical Therapy in the 
Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting Within Eight Hours of Symptom Onset; and SWIFT PRIME, Solitaire FR With the 
Intention for Thrombectomy as Primary Endovascular Treatment.
*Adjusted for age, sex, baseline stroke severity, site of occlusion, intravenous alteplase treatment, Alberta Stroke Program Early CT Score (ASPECTS), and time from 
onset to randomization.
†Modified Rankin scale (mRS) ranges from normal (0) to death (6). Analysis combined mRS 5 and 6.
‡National Institutes of Health Stroke Scale (NIHSS) score (standardized neurological examination) ranges from normal (0) to death (42), 8 point reduction is highly 
clinically significant.
§SICH, Symptomatic intracerebral hemorrhage defined by source trial.
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clot locations, presence or absence of tandem cervical carotid 
occlusion, milder and more severe deficits, milder and more 
severe ischemic injury on initial imaging, and in those who 
received alteplase or were alteplase-ineligible.
Older age has often been used as an exclusion criterion 
for thrombectomy, and indeed 2 of the 4 trials analyzed 
had an upper age limit (SWIFT PRIME and REVASCAT). 
Nonetheless, in patients with good or independent premorbid 
function, there was no evidence of reduced treatment effect 
in the elderly and, moreover, a clinically and statistically sig-
nificant 20% absolute reduction in mortality in patients aged 
≥80 in the SEER trials. There is, therefore, no justification for 
exclusion from thrombectomy purely on the basis of age in 
clinical practice.
Initial analyses of Interventional Management of Stroke 
(IMS-3) and recent combined analysis with MR CLEAN 
focused on stroke severity (NIHSS≥20) as a key determinant 
of endovascular treatment benefit.16,17 Our analyses dem-
onstrated at least as great a treatment benefit in those with 
NIHSS≤15 as in those with NIHSS>20. Although few patients 
were enrolled in the recent trials with NIHSS<6, there is no 
evidence of treatment effect modification across the available 
severity spectrum. Treatment of mild stroke will continue to 
require clinical judgment.18
The preponderance of patients in these trials received 
intravenous alteplase before endovascular thrombectomy 
and fibrinolytic treatment was part of the inclusion criteria 
for EXTEND-IA and SWIFT PRIME. All patients who were 
alteplase-eligible in the analyzed trials were given alteplase. 
These data, therefore, support the continued use of alteplase 
before thrombectomy in all eligible patients. Although there 
were fewer patients in these trials who were alteplase-ineligi-
ble, there was clear benefit of endovascular thrombectomy in 
these patients not candidates for pretreatment with fibrinolytic 
agents, confirming the benefits of endovascular thrombectomy 
in this group.
The crucial effect of time has been emphasized in relation 
to intravenous thrombolysis12,19 and also applies to endovas-
cular therapies.20,21 In the case of alteplase, time to treatment 
is the most commonly analyzed metric as time of reperfusion 
is infrequently documented and may occur several hours post-
treatment. The precise quantification of time to reperfusion 
and the higher frequency of reperfusion with endovascular 
treatment should allow more detailed understanding of the 
Figure 1. Functional outcome (modified Rankin Scale [mRS] at 90 days) in the primary and sensitivity analysis populations. Odds ratios 
(OR) and 95% confidence intervals (CI) for ordinal analysis of mRS (both unadjusted and adjusted for age, sex, baseline stroke severity, 
site of occlusion, intravenous alteplase treatment, Alberta Stroke Program Early CT Score (ASPECTS), and time from onset to randomiza-
tion) and for independent functional outcome (mRS 0–2), both unadjusted and adjusted.
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relationship of time to outcome. The proportion of patients 
with favorable imaging decreases over time such that earlier 
imaging should increase the proportion eligible for treatment 
and the overall beneficial effect to the stroke population.22 Our 
pooled analysis confirmed a time–benefit relationship, with 
decline in frequency of independent outcome with longer onset 
to reperfusion times. However, the effect size is small in this 
analysis, and it is likely that these studies underestimate the 
importance of time because of selective recruitment of patients 
with good quality collateral flow or penumbral profiles. The 
impact of time has previously been shown to be muted in 
patients with favorable imaging profiles.23 Accordingly, in clin-
ical practice, it is essential to streamline systems to minimize 
delays and achieve optimal patient outcomes.
The Solitaire device for stent thrombectomy had an overall 
rate of successful revascularization (mTICI 2b/3) of 236/306 
(77%) across these studies with a low rate of symptomatic 
hemorrhage. Although further device innovation to improve 
the rates of complete reperfusion (mTICI 3) on first pass of the 
device will undoubtedly occur, these results set a clear bench-
mark for future technological development.
In seeking to characterize the effects of the Solitaire stent 
retriever, the inclusion of trials in which other endovascular 
treatments were used has the potential to introduce confounds. 
We eliminated this concern by confining this analysis to stud-
ies that used the Solitaire device in a majority of patients and 
by performing sensitivity analyses confined to the patients 
treated with the Solitaire device.
Limitations of this study include the potential heterogene-
ity in inclusion criteria between studies. However, we found 
no evidence of a study-by-treatment interaction and analysis at 
the level of individual patient data minimizes the risk of bias. 
All of the 4 trials specified that patients were included on the 
basis of imaging, and treatment was conducted quickly once 
imaging eligibility had been ascertained. Thus, certain patient 
groups were not included in the trials in sufficient numbers to 
draw conclusions regarding efficacy. This particularly applies 
to those with large ischemic core, defined using ASPECTS, 
poor collateral grade, or unfavorable penumbral patterns. The 
point estimate for treatment effect was unfavorable in the small 
group of patients with baseline ASPECTS 0 to 5. However, 
benefit was not statistically excluded and may accrue in some 
of these patients, depending on infarct volume, location, and 
patient comorbidities.24 More advanced imaging may improve 
the reliability of core estimation versus noncontrast computed 
tomography and provide greater information about infarct 
topography. This analysis has focused on the endovascular tri-
als using only or predominantly the Solitaire device and does 
Figure 2. Distribution of modified Rankin scores (mRS) at 90 days 
in the primary analysis: SWIFT PRIME, EXTEND-IA, ESCAPE,  
and REVASCAT. Overall results (A) comparing age dichotomized 
at 70 years (B), comparing age dichotomized at 80 years (C), 
comparing those who did or did not receive intravenous alteplase 
before endovascular stent thrombectomy (D). (Continued ) 
Figure 2 Continued. NB mRS 5 and 6  were combined for the 
ordinal analysis. ESCAPE indicates Endovascular Treatment for 
Small Core and Anterior Circulation Proximal Occlusion With 
Emphasis on Minimizing CT to Recanalization Times; EXTEND-
IA, Extending the Time for Thrombolysis in Emergency Neuro-
logical Deficits—Intra-Arterial; REVASCAT, Randomized Trial of 
Revascularization With Solitaire FR Device Versus Best Medical 
Therapy in the Treatment of Acute Stroke Due to Anterior Circu-
lation Large Vessel Occlusion Presenting Within Eight Hours of 
Symptom Onset; and SWIFT PRIME, Solitaire FR With the Inten-
tion for Thrombectomy as Primary Endovascular Treatment.
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not provide detailed evidence regarding other endovascular 
devices or approaches. Further individual patient data meta-
analysis in a broader range of endovascular trials is planned.
This analysis confirms the robust treatment benefits of 
endovascular stent thrombectomy using the Solitaire device in 
patients with large vessel occlusion ischemic stroke, selected 
by imaging and treated rapidly within 6 hours of stroke onset. 
No clinical effect modifiers were identified, indicating that 
age and stroke severity (within the range included in the tri-
als) should not exclude patients from therapy. Effects in later 
time windows and in patients with more extensive irreversible 
brain injury at baseline require further study.
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